

Clinical Trial Review

Contact Ann Bradley, RN BES OCN CCRP
 Research Program Manager
abradley@ohcmail.com for further information

Study Number	Protocol Title	Status
	HEMATOLOGICAL TUMORS	
	Acute Myeloid Leukemia (AML)	
	<i>First Line</i>	
None		
	<i>Relapsed/Refractory</i>	
None		
	Chronic Lymphocytic Leukemia (CLL)	
	<i>First Line</i>	
None		
	<i>Relapsed/Refractory</i>	
None		
	<i>Consolidation/Maintenance Therapy following Second Line Therapy</i>	
CLL 10 CC-5013-CLL-002 Celgene	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Fludarabine-Based Therapy	Open
	Chronic Myelogenous Leukemia (CML)	
	<i>Untreated</i>	
None		
	<i>Treated</i>	
None		
	Myelodysplastic Syndrome	
MDS 07 SCRI Services	A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndrome (MDS) Patients	Open
	Non-Hodgkin's Lymphoma (NHL) - Follicular	
	<i>First Line or Relapsed</i>	
None		
	Non-Hodgkins (NHL) Diffuse Large Cell	
	<i>First Line</i>	
LYM 54 H6Q-MC-S028 Lilly	An Open Label, Randomized, Phase II Study of R-CHOP + Enzastaurin vs R-CHOP in the First Line Treatment of Patients with Intermediate and High-Risk Diffuse B-Cell Lymphoma	Open
	<i>First Line Advanced Indolent NHL/MCL</i>	
LYM 64 C18083/3064/NL/MN Cephalon, Inc.	An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and rituximab (BR) Compared With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkins Lymphoma or Mantle Cell Lymphoma	Open

MULTIPLE MYELOMA		
First Line - BMT, Possible Candidate		
None		
First Line Non - BMT Candidate		
MM 22 C05009 Millennium Pharmaceuticals	Phase IIIb Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma who are not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP)	Open
MM 24 PX-171-003 Proteolix, Inc.	An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma	Open-limited to Kenwood site
SOLID TUMORS		
BLADDER		
None		
BRAIN		
First Line		
None		
BREAST		
Neoadjuvant		
BRE 133 SCRI IIT	Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer	Open
BRE 139 SCRI IIT	Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2- Positive Locally Advanced Breast Cancer	Open
Adjuvant		
NSABP B-44 BETH Trial	A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab	Open - Limited sites
BRE 128 BIG 2-06/N063D/EGF106708	AL TTO aka Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation A Randomized, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer	Open
BRE 145 SCRI Services	Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs AC Followed by Paclitaxel in Patients with Triple-Negative Early Breast Cancer	Open
BRE 131 BO202289 F. Hoffman-LaRoche Ltd.	An International Multi-Centre Open-Label 2-ARM Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer	Open
Locally Advanced/Metastatic, First Line, HER2-		
BRE 154 SCRI Services	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab+/- Everolimus as First-Line Chemotherapy for Patients with HER2-Negative Metastatic Breast Cancer (MBC)	Open
BRE 153 B9E-US-S379(a) Eli Lilly & Company	A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer previously treated with Taxanes	Open

BRE 163 B-46-I/07132 SCRI/US Oncology	Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	Pending
	Metastatic/Refractory, HER2-	
None		
	Metastatic, First Line, HER2+	
BRE 132 TOC4129g/WO20698 Genentech, Inc.	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzamab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2 Positive Metastatic Breast Cancer (CLEOPATRA)	Open
	Metastatic, First or Second Line, HER2+	
BRE 140 LPT111111 GlaxoSmithKline	A Single-arm, Multicenter Phase II Study to Evaluate the Combination of Weekly Nanoparticle Albumin-bound Paclitaxel (nab-Paclitaxel or Abraxane) and Lapatinib (TYKERB) in Women who have Received No More Than One Prior Chemotherapeutic Regimen in the Treatment of Erb/2 Overexpressing Metastatic Breast Cancer.	Open
	Metastatic, Refractory, HER2 +	
None		
	Hormonal	
NSABP B-42	A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer	Open Optional ARM Closed to Enrollment On Hold
BRE 144 SNDX-275-0301 Syndax Pharmaceuticals, Inc.	A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane with or without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor	Open
	Metastatic Observational	
BRE 150 AVF4349n Genentech, Inc.	An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer	Open
	Oncotype Dx Assay	
TAILORx PACCT-1 CTSU	Program for the Assessment of Clinical Cancer Tests Trial Assigning Individualized Options for Treatment	Open
	Radiation	
NSABP B-39	A Randomized Phase 3 Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women w/Stage 0,I or II Breast Cancer	Open
	COLORECTAL	
	Neoadjuvant Rectal	
NSABP R-04	A Clinical Trial comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum	Open
	Adjuvant Colon	
None		
	Unresectable	
None		

	Metastatic First Line	
None		
	Metastatic Second Line	
None		
	ESOPHAGEAL	
	Localized, Stage I-III, Neoadjuvant	
None		
	Metastatic	
None		
	GASTRIC	
None		
	GYNECOLOGICAL	
	Ovarian III-IV, First Line	
GYN 19 SCRI IIT	A Randomized Phase II Study of Paclitaxel/Carboplatin With and without Sorafenib on the First-Line treatment of Patients with Stage III/IV Epithelial Ovarian Cancer	Open
	Endometrial- Advanced 2nd Line	
GYN 22 AP23573-07-205 ARIAD	A Randomized, Phase II Trial of Deforolimus (AP23573;MK-8669) Compared to Progestin in Female Adult Patients with Advanced Endometrial Carcinoma Following One Line of Chemotherapy	Open
	Recurrent Ovarian, Fallopian Tube and Primary Peritoneal	
GYN 24 AVF 4095g Genentech	A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal or Fallopian Tube Carcinoma	Open
	KIDNEY	
	Adjuvant	
ECOG E2805 CTSU	A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma	Open- on hold
	Advance/Metastatic/First Line	
GU 43 SCRI IIT	A Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma	Open
GU 59 VEG108844 GlaxoSmithKline	A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advance and/or Metastatic Renal Carcinoma	Open
GU 44 SCRI IIT	A Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma	Open
	Metastatic, Relapsed/Refractory	
GU 43 SCRI IIT	A Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma	Open
GU 44 SCRI IIT	A Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma	Open
GU 49 SCRI Services	A Phase II Study of LBH589 in the Treatment of Patients with Refractory Clear Cell renal Carcinoma	Open
GU 56 SCRI IIT	A Phase II Trial of Pazopanib in Patients with Metastatic Renal Cell Carcinoma Previously Treated with sunitinib or bevacizumab	Open
GU 58 A4061032 Pfizer, Inc.	Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: Axis Trial	Open

LIVER- Hepatocellular		
GI 121 A6181170 Pfizer, Inc.	A Multinational, Randomized, Double-blind, Open Label, Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma	Open
NON-SMALL CELL LUNG		
Neoadjuvant Select Stage IB, II, and III		
LUN 186 SCRI IIT	Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer	Open
Adjuvant/Post-Op		
LUN 142 SCRI IIT	A Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Avastin, and Erlotinib versus Chemotherapy alone in Patients with Resected Non-Small Cell Lung Cancer	Open
First Line, Advanced		
Pharmatech NSC PSHC108-009	A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-line Treatment of Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)	Open
LUN 179 SCRI IIT	Phase II Trial of Ixabepilone and Carboplatin with or without Bevacizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer	Open Cohort A closed
First Line, Advanced, Elderly		
LUN 139 SCRI IIT	A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab (Avastin) or Pemetrexed/Carboplatin/Bevacizumab (Avastin) in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer	Open
Stage IIIB/IV, First Line		
LUN 192 H3E-MC-JMHD(a) Eli Lilly & Company	Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-small Cell Lung Cancer	Open
First Line, Poor Performance, Advanced		
LUN 196 SCRI Service	TOPPS (Trial of Poor Performance Status patients): Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage III/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2	Open
Relapsed/Refractory Stage III		
LUN 187 H3E-MC-JMIG Eli Lilly & Company	Phase III Study of Pemetrexed, Cisplatin and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology	Open
LUNG SMALL CELL		
Extensive Stage First Line		
LUN 156 SCRI IIT	Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer	Open
Extensive Stage Second Line/Relapsed		
LUN 198 A6012212US Nippon Kayaku Co.,	A Phase II Study of NK012 in Sensitive and Refractory Relapsed Small-Cell Lung cancer (SCLC)	Open

